Patents by Inventor Steen Lisby

Steen Lisby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9540433
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: January 10, 2017
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • Patent number: 9492565
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 15, 2016
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Patent number: 9428582
    Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 30, 2016
    Assignee: GENMAB A/S
    Inventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
  • Patent number: 9168314
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 27, 2015
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Patent number: 9040050
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 26, 2015
    Assignee: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • Publication number: 20140030273
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: February 1, 2012
    Publication date: January 30, 2014
    Applicant: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • Publication number: 20130101608
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: June 15, 2011
    Publication date: April 25, 2013
    Applicant: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Publication number: 20130004480
    Abstract: Use of CD20 binding molecules, such as anti-CD20 antibodies, for the treatment of chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: July 4, 2007
    Publication date: January 3, 2013
    Inventors: Paul Parren, Steen Lisby, Ole Baadsgaard
  • Publication number: 20100150936
    Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
    Type: Application
    Filed: July 3, 2007
    Publication date: June 17, 2010
    Applicant: GENMAB A/S
    Inventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
  • Publication number: 20100092489
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 26, 2007
    Publication date: April 15, 2010
    Applicant: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby